Northern Trust’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.63M | Buy |
883,578
+24,592
| +3% | +$307K | ﹤0.01% | 2103 |
|
|
2025
Q4 | $11.1M | Sell |
858,986
-38,134
| -4% | -$490K | ﹤0.01% | 2025 |
|
|
2025
Q3 | $11.6M | Sell |
897,120
-238,340
| -21% | -$3.18M | ﹤0.01% | 2029 |
|
|
2025
Q2 | $20.2M | Sell |
1,135,460
-99,979
| -8% | -$1.74M | ﹤0.01% | 1636 |
|
|
2025
Q1 | $22M | Sell |
1,235,439
-48,911
| -4% | -$1.11M | ﹤0.01% | 1572 |
|
|
2024
Q4 | $38.3M | Buy |
1,284,350
+360,841
| +39% | +$7.64M | 0.01% | 1289 |
|
|
2024
Q3 | $14.4M | Buy |
923,509
+422,060
| +84% | +$7.65M | ﹤0.01% | 1836 |
|
|
2024
Q2 | $8.59M | Buy |
501,449
+3,661
| +0.7% | +$64.4K | ﹤0.01% | 2086 |
|
|
2024
Q1 | $7.78M | Buy |
497,788
+3,072
| +0.6% | +$45.2K | ﹤0.01% | 2201 |
|
|
2023
Q4 | $7.39M | Buy |
494,716
+55,671
| +13% | +$745K | ﹤0.01% | 2267 |
|
|
2023
Q3 | $7.09M | Sell |
439,045
-143,992
| -25% | -$4.15M | ﹤0.01% | 2226 |
|
|
2023
Q2 | $24.2M | Sell |
583,037
-34,381
| -6% | -$2.13M | ﹤0.01% | 1458 |
|
|
2023
Q1 | $37.1M | Buy |
617,418
+14,329
| +2% | +$1.15M | 0.01% | 1140 |
|
|
2022
Q4 | $44.2M | Buy |
603,089
+3,081
| +0.5% | +$232K | 0.01% | 994 |
|
|
2022
Q3 | $45.6M | Sell |
600,008
-20,603
| -3% | -$1.61M | 0.01% | 916 |
|
|
2022
Q2 | $43.1M | Sell |
620,611
-16,626
| -3% | -$1.25M | 0.01% | 976 |
|
|
2022
Q1 | $52.8M | Buy |
637,237
+3,006
| +0.5% | +$221K | 0.01% | 988 |
|
|
2021
Q4 | $47.6M | Sell |
634,231
-660
| -0.1% | -$66.2K | 0.01% | 1132 |
|
|
2021
Q3 | $73.8M | Buy |
634,891
+50,087
| +9% | +$7.57M | 0.01% | 819 |
|
|
2021
Q2 | $130M | Buy |
584,804
+19,524
| +3% | +$3.8M | 0.02% | 569 |
|
|
2021
Q1 | $74.7M | Buy |
565,280
+932
| +0.2% | +$147K | 0.01% | 832 |
|
|
2020
Q4 | $97.7M | Buy |
564,348
+102,760
| +22% | +$14.1M | 0.02% | 649 |
|
|
2020
Q3 | $51.4M | Buy |
461,588
+163,010
| +55% | +$13M | 0.01% | 891 |
|
|
2020
Q2 | $17.7M | Sell |
298,578
-650,544
| -69% | -$42.8M | ﹤0.01% | 1719 |
|
|
2020
Q1 | $63.9M | Sell |
949,122
-38,456
| -4% | -$3.04M | 0.02% | 648 |
|
|
2019
Q4 | $83.2M | Sell |
987,578
-35,055
| -3% | -$2.83M | 0.02% | 681 |
|
|
2019
Q3 | $76.5M | Buy |
1,022,633
+138,177
| +16% | +$11M | 0.02% | 676 |
|
|
2019
Q2 | $55.9M | Buy |
884,456
+93,128
| +12% | +$4.72M | 0.01% | 912 |
|
|
2019
Q1 | $38.1M | Buy |
791,328
+11,098
| +1% | +$534K | 0.01% | 1190 |
|
|
2018
Q4 | $26.1M | Sell |
780,230
-24,241
| -3% | -$886K | 0.01% | 1350 |
|
|
2018
Q3 | $42.2M | Buy |
804,471
+47,512
| +6% | +$1.89M | 0.01% | 1156 |
|
|
2018
Q2 | $23.7M | Buy |
756,959
+199,998
| +36% | +$5.56M | 0.01% | 1649 |
|
|
2018
Q1 | $12.1M | Sell |
556,961
-2,975
| -0.5% | -$64K | ﹤0.01% | 2038 |
|
|
2017
Q4 | $11.3M | Sell |
559,936
-18,935
| -3% | -$365K | ﹤0.01% | 2111 |
|
|
2017
Q3 | $11.5M | Sell |
578,871
-8,827
| -2% | -$173K | ﹤0.01% | 2113 |
|
|
2017
Q2 | $10.2M | Buy |
587,698
+78,047
| +15% | +$1.01M | ﹤0.01% | 2173 |
|
|
2017
Q1 | $4.13M | Buy |
509,651
+31,897
| +7% | +$230K | ﹤0.01% | 2675 |
|
|
2016
Q4 | $3.75M | Buy |
477,754
+11,142
| +2% | +$89.6K | ﹤0.01% | 2737 |
|
|
2016
Q3 | $3.98M | Sell |
466,612
-13,054
| -3% | -$119K | ﹤0.01% | 2666 |
|
|
2016
Q2 | $5.6M | Buy |
479,666
+404,961
| +542% | +$5.07M | ﹤0.01% | 2382 |
|
|
2016
Q1 | $1.08M | Buy |
74,705
+259
| +0.3% | +$3.72K | ﹤0.01% | 3228 |
|
|
2015
Q4 | $1.67M | Buy |
+74,446
| New | +$1.78M | ﹤0.01% | 3147 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Northern Trust's NVCR Position: Q1 2026 in Review
Northern Trust increased its NovoCure (NVCR) stake by 2.9% in Q1 2026, buying an estimated $307K and bringing the position to 883,578 shares worth $9.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.
Northern Trust first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $130M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Northern Trust held 883,578 shares of NovoCure worth $9.63M as of Q1 2026.
- Northern Trust bought 24,592 NovoCure shares in Q1 2026, an estimated $307K.
- NovoCure made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2103 holding.
- Northern Trust first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
- Northern Trust's NovoCure position peaked at $130M in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.